Related Experiment Video
Updated: Jan 24, 2026

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
Published on: June 17, 2015
Pseudopeptide Designed to Inhibit Oligomerization and Redox Chemistry in Alzheimer?s Disease
Stanley K A Opare1, Arvi Rauk1
1Department of Chemistry , The University of Calgary , Calgary , Alberta Canada , T2N 1N4.
Abstract:
Aggregation of amyloid beta peptide (A?) and inflammatory processes associated with the generation of superoxide, hydrogen peroxide, and hydroxyl radicals are responsible for neurotoxicity in Alzheimer?s disease. The latter are a result of the redox activity of copper-bound A? complexes with molecular oxygen. A ligand (PI1), previously designed to compete with A? for copper, and a pseudopeptide (SGC1) with a property of breaking the self-aggregation of A?, are attached to each other to form a new pseudopeptide (TGC1) in this study. Using a combination of density functional theory and molecular dynamics simulations, we show that TGC1 should have the ability to inhibit self-aggregation of A?, prevent the binding of copper to A?, and quench the redox activity of the copper. This trifunctional ligand is a good candidate for development into an anti-Alzheimer drug.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Balancing Redox Equations
Redox Reactions
Redox Reactions
Feedback Inhibition

